Mechanistic Validation of Potential Anti-Breast Cancer Therapeutics

Mechanistic Validation of Potential Anti-Breast Cancer Therapeutics

Bibliographic Details
Main Author:	Chuang, Hsiao-Ching
Language:	English
Published:	The Ohio State University / OhioLINK 2012
Subjects:	Biomedical Research Pharmacy Sciences &945 -tocopheryl succinate anti-adhesion triple-negative breast cancer PARP inhibitor
Online Access:	http://rave.ohiolink.edu/etdc/view?acc_num=osu1338213365

Similar Items

Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
by: Mehanna J, et al.
Published: (2019-07-01)

Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes
by: Anna Diana, et al.
Published: (2020-03-01)

HEREDITARY BREAST CANCER
by: E. M. Bit-Sava, et al.
Published: (2016-02-01)

Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
by: Inna P. Ganshina, et al.
Published: (2021-02-01)

Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review
by: Claire H. Li, et al.
Published: (2019-12-01)

Co-delivery nanocarriers targeting folate receptor and encapsulating 2-deoxyglucose and α-tocopheryl succinate enhance anti-tumor effect in vivo
by: Lei X, et al.
Published: (2017-08-01)

Chemo-Immunotherapy of Murine Cancer Using Alpha Tocopheryl Succinate and Non-Matured Dendritic Cells
by: Ramanathapuram, Lalitha
Published: (2006)

PARP inhibitors in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. Experience of treatment with talazoparib in clinical practice
by: M. A. Frolova, et al.
Published: (2020-07-01)

An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer
by: Erica M. Stringer-Reasor, et al.
Published: (2021-03-01)

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
by: Xiuzhi Zhu, et al.
Published: (2021-04-01)

A review of current progress in triple-negative breast cancer therapy
by: Shen Meiying, et al.
Published: (2020-11-01)

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
by: Man Yee Keung, et al.
Published: (2020-03-01)

The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency
by: Yayun Gu, et al.
Published: (2021-02-01)

Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells
by: Matthews M. Malka, et al.
Published: (2021-07-01)

Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer
by: Michela Palleschi, et al.
Published: (2021-07-01)

Triptolide interferes with XRCC1/PARP1-mediated DNA repair and confers sensitization of triple-negative breast cancer cells to cisplatin
by: Zhiwei Zhang, et al.
Published: (2019-01-01)

The influence of vitamin E supplementation on the oxidative status of rat liver
by: Đurašević S.F., et al.
Published: (2010-01-01)

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting
by: Tesa M. Severson, et al.
Published: (2017-08-01)

Topical anesthesia therapy using lidocaine-loaded nanostructured lipid carriers: tocopheryl polyethylene glycol 1000 succinate-modified transdermal delivery system
by: Zhao X, et al.
Published: (2018-12-01)

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
by: Man Yee T. Keung, et al.
Published: (2019-03-01)

CRISPR/Cas9‐mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1‐mutated breast cancer cells
by: Rachel L. Mintz, et al.
Published: (2020-01-01)

Anti-metastatic and anti-proliferative activity of eugenol against triple negative and HER2 positive breast cancer cells
by: Mashan L. Abdullah, et al.
Published: (2018-12-01)

Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer
by: Camille Franchet, et al.
Published: (2021-08-01)

Design and Development of D‒α‒Tocopheryl Polyethylene Glycol Succinate‒<i>block</i>‒Poly(ε-Caprolactone) (TPGS−<i>b</i>−PCL) Nanocarriers for Solubilization and Controlled Release of Paclitaxel
by: Osman Yusuf, et al.
Published: (2021-05-01)

Triple Negative Breast Cancer: A review of common therapeutic Targets and Current Treatment options.
by: Daud Akhtar, et al.
Published: (2017-06-01)

Approach to the Triple Negative Breast Cancer in New Drugs Area
by: Mehrzad Mirzania
Published: (2016-04-01)

ANGPTL4 overexpression inhibits tumor cell adhesion and migration and predicts favorable prognosis of triple-negative breast cancer
by: Yu-Chen Cai, et al.
Published: (2020-09-01)

PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
by: Anthony Gonçalves, et al.
Published: (2020-05-01)

PARP1 expression in breast cancer and effects of its inhibition in preclinical models
by: García Parra, Jetzabel, 1983-
Published: (2012)

High Glucose Represses the Anti-Proliferative and Pro-Apoptotic Effect of Metformin in Triple Negative Breast Cancer Cells
by: Sharon Varghese, et al.
Published: (2019-01-01)

Tocopheryl Succinate-Induced Structural Changes in DPPC Liposomes: DSC and ANS Fluorescence Studies
by: Grażyna Neunert, et al.
Published: (2020-06-01)

Primary Osteosarcoma of the Breast with Extensive Chondroid Matrix in a Teenager Female Patient: The Paradoxical Diagnosis in Breast Mastopathy
by: Yahaya JJ, et al.
Published: (2020-01-01)

Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer
by: Meizhuo Gao, et al.
Published: (2020-03-01)

A Novel Specific Anti-CD73 Antibody Inhibits Triple-Negative Breast Cancer Cell Motility by Regulating Autophagy
by: Zheng Qiao, et al.
Published: (2019-02-01)

Self-nanoemulsifying drug-delivery systems for potentiated anti-inflammatory activity of diacerein
by: Eltobshi AA, et al.
Published: (2018-10-01)

A clinicopathologic study of triple negative breast cancer
by: Vandana L Gaopande, et al.
Published: (2015-01-01)

STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
by: Jiang-Jiang Qin, et al.
Published: (2019-05-01)

Recent developments in d-α-tocopheryl polyethylene glycol-succinate-based nanomedicine for cancer therapy
by: Songwei Tan, et al.
Published: (2017-01-01)

α-Tocopheryl Succinate-Based Polymeric Nanoparticles for the Treatment of Head and Neck Squamous Cell Carcinoma
by: Carolina Sánchez-Rodríguez, et al.
Published: (2018-09-01)

A chalcone-syringaldehyde hybrid inhibits triple-negative breast cancer cell proliferation and migration by inhibiting CKAP2-mediated FAK and STAT3 phosphorylation
by: Jin, X.-X, et al.
Published: (2022)

Cannot write session to /tmp/vufind_sessions/sess_btp9e205gtunqs5j2ffo5ev82p